ProPhase Labs, Inc. (NASDAQ:PRPH) Short Interest Update

by · The Cerbat Gem

ProPhase Labs, Inc. (NASDAQ:PRPH – Get Free Report) was the target of a significant decrease in short interest in February. As of February 28th, there was short interest totalling 1,660,000 shares, a decrease of 62.4% from the February 13th total of 4,420,000 shares. Currently, 8.8% of the company’s stock are sold short. Based on an average daily volume of 8,860,000 shares, the short-interest ratio is currently 0.2 days.

ProPhase Labs Stock Performance

PRPH traded down $0.03 during trading on Thursday, reaching $0.43. 786,944 shares of the company’s stock were exchanged, compared to its average volume of 11,928,803. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33. ProPhase Labs has a 1 year low of $0.22 and a 1 year high of $7.48. The company’s fifty day simple moving average is $0.47 and its 200-day simple moving average is $1.26. The stock has a market capitalization of $10.16 million, a P/E ratio of -0.34 and a beta of -0.53.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of ProPhase Labs in a report on Tuesday, February 25th. They set a “sell” rating on the stock.

Check Out Our Latest Stock Report on ProPhase Labs

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Sheets Smith Wealth Management purchased a new position in shares of ProPhase Labs during the 4th quarter valued at approximately $158,000. Perritt Capital Management Inc increased its holdings in ProPhase Labs by 129.1% in the fourth quarter. Perritt Capital Management Inc now owns 190,000 shares of the company’s stock valued at $144,000 after buying an additional 107,068 shares in the last quarter. Warberg Asset Management LLC acquired a new position in shares of ProPhase Labs in the fourth quarter worth about $77,000. Renaissance Technologies LLC boosted its stake in shares of ProPhase Labs by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock worth $217,000 after acquiring an additional 71,375 shares in the last quarter. Finally, HighTower Advisors LLC grew its position in shares of ProPhase Labs by 32.2% during the 4th quarter. HighTower Advisors LLC now owns 236,781 shares of the company’s stock valued at $179,000 after acquiring an additional 57,736 shares during the period. 9.45% of the stock is currently owned by hedge funds and other institutional investors.

About ProPhase Labs

(Get Free Report)

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

See Also